Key statistics
On Monday, HUTCHMED (China) Ltd (13:HKG.HS) closed at 27.50, -23.40% below its 52-week high of 35.90, set on May 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.10 |
---|---|
High | 28.30 |
Low | 27.00 |
Bid | 27.45 |
Offer | 27.50 |
Previous close | 28.35 |
Average volume | 4.53m |
---|---|
Shares outstanding | 871.56m |
Free float | 501.29m |
P/E (TTM) | -- |
Market cap | 24.71bn HKD |
EPS (TTM) | -0.3881 HKD |
Data delayed at least 15 minutes, as of Nov 11 2024 08:08 GMT.
More ▼
Announcements
- Clinical Data to be Presented at ASH and ESMO Asia
- HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
- First Commercial Milestone Payment
- Total Voting Rights
- HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
- Vesting of awards under the LTIP
- SAVANNAH: clinically meaningful response rate
- HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
- Japan Approval for FRUZAQLA
- HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
More ▼